Document is current
Any future updates will be listed below
-
Authors
Sako, Wataru http://orcid.org/0000-0003-2009-2486
Kogo, Yuki http://orcid.org/0000-0002-8120-3971
Koebis, Michinori
Kita, Yoshiaki http://orcid.org/0000-0002-0642-4555
Yamakage, Hajime
Ishida, Takayuki
Hattori, Nobutaka http://orcid.org/0000-0002-2034-2556
-
Funding
Funding for this research was provided by:
Eisai
- License Information
-
More Information
Article History
Received: 13 June 2023
Accepted: 6 October 2023
First Online: 19 October 2023
Competing interests
: The authors declare no competing non-financial interests but the following competing financial interests; W.S. has received honoraria from Eisai Co. Ltd, Kyowa Kirin Co. Ltd, Sumitomo Pharma Co. Ltd, and Takeda Pharmaceutical Co. Ltd; has received research support from Mitsubishi Tanabe Pharma Co. and JSPS KAKENHI. Y.Kogo, M.K., T.I. are employees of Eisai Co., Ltd. Y.Kita provided medical writing support, funded by Eisai Co., Ltd. H.Y. performed statistical analysis, funded by Eisai Co., Ltd. N.H. received personal fees from Meiji Seika Pharma Co., Ltd. during the conduct of the submitted work; grants from Ono Pharmaceutical Co., Ltd., FP Corp., Eisai Co., Ltd., and Nihon Mediphysics Co., Ltd.; personal fees from Sumitomo Dainippon Pharma Co., Ltd., Otsuka Pharmaceutical Co., Ltd., Takeda Pharmaceutical Co., Ltd., Kyowa Hakko-Kirin Co., Ltd., Nippon Boehringer Ingelheim Co., Ltd., FP Corp., Eisai Co., Ltd., Kissei Pharmaceutical Co., Ltd., Nihon Medi-physics Co., Ltd., Novartis Pharma K.K., Biogen Idec Japan Ltd., AbbVie GK, Boston Scientific Japan K.K., Sanofi K.K., Alexion Pharmaceuticals, Inc., Mylan N.V., Daiichi Sankyo Co., Ltd., Hisamitsu Pharmaceuticals Co., Inc., and Kao Corp.; and reports donations to the department, endowed research departments and joint collaborative research departments from Sumitomo Dainippon Pharma Co., Ltd., Otsuka Pharmaceutical, Co., Ltd., Takeda Pharmaceutical Co., Ltd., Kyowa Hakko-Kirin Co., Ltd., Nippon Boehringer Ingelheim Co., Ltd., Eisai Co., Ltd., GSK K.K., Kissei Pharmaceutical Co. Ltd., Novartis Pharma K.K., Nihon Medi-physics Co., Ltd., Biogen Idec Japan Ltd., AbbVie GK, Medtronic, Inc., Boston Scientific Japan K.K., Ono Pharmaceutical Co., Ltd., Hydrogen Health Medical Labo Co., ABIST Co., Ltd., Daiwa Co., Ltd., Bayer Yakuhin Ltd., Nihon Pharmaceutical Co., Ltd., Asahi Kasei Medical Co., Ltd., MiZ Co., Ltd., Mitsubishi Tanabe Pharma Corporation, Daiichi Sankyo Co. Ltd., and OHARA Pharmaceutical Co., Ltd. outside the submitted work.
